We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Method Rapidly Monitors Sickle Cell Disease

By LabMedica International staff writers
Posted on 26 Jun 2019
Print article
Image: A peripheral blood film from a patient with sickle cell disease (Photo courtesy of Venngage).
Image: A peripheral blood film from a patient with sickle cell disease (Photo courtesy of Venngage).
Sickle cell disease (SCD) is a hereditary disorder that affects red blood cells, distorting their natural disc shape into a crescent moon or "sickle" shape. Normal red blood cells move freely through small vessels throughout the body to deliver oxygen. With sickle cell disease, the misshapen red blood cells become hard and sticky, making it difficult for them to move through blood vessels.

Sickle cell disease affects millions of people of many nationalities throughout the world, including both children and adults. A major challenge in managing the disease is the tremendous pain that patients endure from chronic and acute pain episodes called pain crisis. Unfortunately, these pain episodes are unpredictable and patients never know when or where these episodes will take place.

Bioengineers at the Florida Atlantic University (Boca Raton, FL, USA) and their hematologist colleague have developed a rapid and reliable new method to continuously monitor sickle cell disease using a microfluidics-based electrical impedance sensor. This novel technology can characterize the dynamic cell sickling and unsickling processes in sickle blood without the use of microscopic imaging or biochemical markers. The team collected five blood samples from individuals with SCD. A normal blood sample was obtained from a local blood bank and used as a control in the study. All samples were stored at 4 °C and tested within two weeks of collection.

Normalized impedance of all the five samples during the first hypoxia session were compared, allowing the scientists to identify intersample variations. The difference in sickling behavior was substantial. The team also established the correlations between the in vitro measurements and the patients' hematological parameters, such as the levels of sickle hemoglobin (HbS) and fetal hemoglobin (HbF). These findings show a potential clinical relevance because it serves as a proof-of-concept of electrical impedance as a label-free, biophysical marker of cell sickling events as well as a sensitive tool for probing the dynamic cellular and subcellular processes beyond the optical microscopy. The developed electrical impedance sensor may potentially be used for assessing vaso-occlusion risk, disease severity, and therapeutic treatment in sickle cell disease.

Sarah E. Du, PhD, an assistant professor and senior author of the study said, “The combination of electrical impedance measurement and on-chip hypoxia control provides a promising method for rapid assessment of the dynamic processes of cell sickling and unsickling in patients with sickle cell disease. In addition, electrical impedance measurement is naturally quantitative, real-time, and offers a convenience in direct or indirect contact with the samples of interest, allowing integrations to microfluidics platform and optical microscopy.” The study was published on May 14, 2019, in the journal ACS Sensors.

Related Links:
Florida Atlantic University

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.